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Abstract
Background: The aim of the present study was to analyze the expression of eukaryotic translation initiation factor 4 
gamma 1 (EIF4G1) in nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including 
patients' survival time.
Methods: Using real-time PCR, we detected the expression of EIF4G1 in normal nasopharyngeal tissues, immortalized 
nasopharyngeal epithelial cell lines NP69, NPC tissues and cell lines. EIF4G1 protein expression in NPC tissues was 
examined using immunohistochemistry. Survival analysis was performed using Kaplan-Meier method. The effect of 
EIF4G1 on cell invasion and tumorigenesis were investigated.
Results: The expression levels of EIF4G1 mRNA were significantly greater in NPC tissues and cell lines than those in the 
normal nasopharyngeal tissues and NP69 cells (P < 0.001). Immunohistochemical analysis revealed that the expression 
of EIF4G1 protein was higher in NPC tissues than that in the nasopharyngeal tissues (P < 0.001). In addition, the levels of 
EIF4G1 protein in tumors were positively correlated with tumor T classification (P = 0.039), lymph node involvement (N 
classification, P = 0.008), and the clinical stages (P = 0.003) of NPC patients. Patients with higher EIF4G1 expression had 
shorter overall survival time (P = 0.019). Multivariate analysis showed that EIF4G1 expression was an independent 
prognostic indicator for the overall survival of NPC patients. Using shRNA to knock down the expression of EIF4G1 not 
only markedly inhibited cell cycle progression, proliferation, migration, invasion, and colony formation, but also 
dramatically suppressed in vivo xenograft tumor growth.
Conclusion: Our data suggest that EIF4G1 can serve as a biomarker for the prognosis of NPC patients.
Introduction
Nasopharyngeal carcinoma (NPC) is a common malig-
nant disease in Southern China where its annual inci-
dence rate is more than 20 cases per 100,000 populations.
Men are twice as likely to develop NPC as women. The
incidence generally increases from ages 20 to 50 [1].
Because the primary anatomical site of tumor growth is
located in a cryptic area and the disease is usually asymp-
tomatic at early stages, the NPC patients tend to present
at a more advanced stage with higher metastatic poten-
tial. Therefore, it is of great interest to find effective bio-
markers for early diagnosis of as well as therapeutic
targets for this malignancy.
The tumorigenesis and metastasis of NPC are complex
and continuous processes that involve a cascade of onco-
gene activations [1,2]. Latent membrane protein 1
(LMP1), a protein encoded by Epstein-Barr virus (EBV),
is considered as a major oncogenic protein promoting the
development of NPC. LMP1-positive cells have greater
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mobility, leading to higher metastatic potential [3] and
faster disease progression [4]. Protein XBP-1  induces
LMP1 expression, and knockdown of XBP-1 blocks up-
regulation of LMP1 in NPC cells. Furthermore, XBP-1
significantly correlates with LMP1  expression in NPC
tumor biopsies, suggesting that XBP-1  can promote
virus-associated cancer in a unique way by driving
expression of a viral oncogene [5]. Survivin is an inhibitor
of apoptosis and promoter of cell proliferation, and it is
usually absent in normal adult tissues but present in
numerous tumors [6]. In NPC, survivin has been con-
stantly found to be over-expressed [7]. Inhibiting survivin
expression can decrease NPC cell viability as well as
increase tumor radiosensitivity [8].
In a previous study, we investigated differentially
expressed genes between non-cancerous nasopharyngeal
tissues and NPC tissues using cDNA microarray. One of
the genes showed markedly increased expression in NPC
was eukaryotic translation initiation factor (EIF4G1) [7].
EIF4G1 participates in protein translation by serving as a
scaffold for several other initiation factors [9]. In addi-
tion, recent studies have found that EIF4G1 possesses
tumorigenesis activities including promoting angiogene-
sis [10], inducing malignant transformation [11], and
inhibiting apoptosis [12]. In a variety of cancers, includ-
ing NPC, lung cancer, and breast cancer, the expression
levels of EIF4G1 are significantly up-regulated [13-16].
In the present study, we investigated the role of EIF4G1
in the pathogenesis of NPC, and examined its association
with clinicopathologic features, including the survival of
patients with NPC. We identified the effects of EIF4G1
on cell growth, invasion, and in vivo tumorigenesis, con-
firmed the increased expression levels of EIF4G1 in pri-
mary NPC tissues and cell lines, and found an inverse
correlation between the levels of EIF4G1 and clinical out-
come of patients with NPC.
Results
EIF4G1 Was Highly Expressed in NPC Tissues and Cell Lines
We first set out to confirm our previous observation that
EIF4G1 was a differentially expressed gene between nor-
mal and cancerous nasopharyngeal tissues. Using real-
time PCR to measure the expression of EIF4G1  tran-
scripts, we found that EIF4G1  expression was signifi-
cantly increased in freshly isolated NPC tissues (n = 10)
and NPC cell lines (n = 6) in comparison to freshly iso-
lated nasopharyngeal tissues (n = 7) and the immortal-
ized human nasopharyngeal epithelial cell lines NP69
(Figure 1A) (P < 0.001). Among the 6 NPC cell lines, 5-8F
cells had the highest expression levels of EIF4G1 (Figure
1A); this cell line is also highly tumorigenic and meta-
static [17,18], suggesting of 5-8F cells as a good model
system for studying the functions of endogenous EIF4G1
by loss-of-function approach.
In addition to the transcript level, using immunohis-
tochemistry, we also found that the levels of EIF4G1 pro-
tein were significantly greater in formalin-fixed paraffin-
embedded (FFPE) NPC tissue samples (n = 137) than the
non-cancerous nasopharyngeal tissue samples (n = 53) (P
< 0.001) (Table 1). We observed the expression of EIF4G1
protein in the cytoplasm of non-cancerous and malignant
nasopharyngeal epithelial cells (Figure 1B).
Relationship between Clinicopathological Characteristics 
and EIF4G1 Expression in Patients with NPC
The relationship between clinicopathological characteris-
tics and EIF4G1 expression in patients with NPC is sum-
marized in Table 1. We did not find any significant
association of EIF4G1 expression with age, sex, smoking
status, or distant metastasis (M classification) in 132
patients with NPC. However, we observed that the levels
of EIF4G1 expression were closely correlated with the T
classification (T1-T2 vs. T3-T4) (P = 0.039), lymph node
involvement (N classification, N0-N1 vs. N2-N3) (P  =
0.008), and clinical stage (I-II vs. III-IV) (P = 0.003) in
NPC patients.
To investigate the prognostic value of EIF4G1 for NPC,
we assessed the association between the levels of EIF4G1
expression and patients' survival time in 107 NPC cases
with prognosis information available. We observed that
the expression levels of EIF4G1 were significantly related
to the overall survival of NPC patients. Patients with high
levels of EIF4G1  expression had significantly shorter
overall survival time than those with low levels of EIF4G1
expression (P = 0.019) (Figure 1C). To estimate the clini-
cal significance of various prognostic factors that might
influence the survival and tumor progression in NPC
patients, univariate analyses were performed. As summa-
rized in Table 2, the lymph node involvement (N classifi-
cation) (P = 0.032), clinical stage (P = 0.023), and high
expression of EIF4G1 (P = 0.014) were statistically signifi-
cant risk factors affecting the overall survival of NPC
patients. To determine the independent prognostic
effects of these variables, multivariate analyses were per-
formed using the Cox's proportional hazards model.
Results showed that only high expression of EIF4G1 can
independently predict the overall survival of NPC
patients (P = 0.027) (Table 2). Taken together, our find-
ings indicate that the levels of EIF4G1 expression could
serve as an effective biomarker for the prognosis of NPC
patients.
Reduced EIF4G1 Expression Suppressed the Proliferation, 
Cell Cycle Progression, Migration, and Invasion of NPC Cells 
in vitro
To study the biological function of EIF4G1, we used a len-
tiviral vector containing shRNA specifically targeting
EIF4G1 to stably knock down the endogenous expressionTu et al. Molecular Cancer 2010, 9:78
http://www.molecular-cancer.com/content/9/1/78
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of EIF4G1 in 5-8F cells, an NPC cell line with high levels
of endogenous EIF4G1. As shown in Figure 2A, compar-
ing to the control (shRNA-Ctrl), cells transfected with
shRNA-EIF4G1  had significantly decreased levels of
EIF4G1 protein.
Subsequently, we examined the effect of decreased
EIF4G1  expression on NPC cell growth in vivo. Using
MTT assay, we found that the parental NPC 5-8F cells
had a similar growth rate as shRNA-Ctrl cells over a
seven-day period, while starting from day 2 the growth of
shRNA-EIF4G1  cells was significantly slower than the
former two cells (P < 0.05) (Figure 2B). Interestingly, the
consistent result also appeared in the plate clone forma-
tion test. Both the parental 5-8F cells and the shRNA-Ctrl
cells formed a similar number of colonies on plate over a
two-week period [(73 ± 3.6) vs. (74.3 ± 4.93)]. In contrast,
knocking down endogenous EIF4G1 could dramatically
reduce the number of colonies (40 ± 5.0) (P < 0.05) (Fig-
ure 2C).
We also measured the alteration of cell cycle progres-
sion by EIF4G1 knock-down. Using flow cytometry anal-
ysis, we found that EIF4G1-deficient cells showed a
Figure 1 The increased expression levels of EIF4G1 mRNA and protein in NPC tumor tissue and cell lines and their association with the over-
all survival of NPC patients. A. EIF4G1 mRNA expression in NPC cell lines, tumor tissues, and non-cancerous nasopharyngeal (NP) tissues. EIF4G1 
mRNA level was relatively high in NPC tissue, NPC cell lines (except 6-10B cells) comparing to nasopharyngeal tissue and NP69 cells. B. EIF4G1 protein 
expression in NPC and nasopharyngeal tissues.(1) Negative control; (2) Weak expression of EIF4G1 in nasopharyngeal tissues; (3-5) Strong expression 
of EIF4G1 in NPC tissues (magnification 400×). C. Kaplan--Meier survival analysis of the overall survival time in 107 NPC patients based on the levels of 
EIF4G1 protein expression. The log-rank test was used.Tu et al. Molecular Cancer 2010, 9:78
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significant increase in S phase proportion and a decrease
in G2/M proportion com pared to the shRNA-C trl and
the parental 5-8F cells (P < 0.05) (Figure 3A).
Cell migration and invasion are integral steps for the
process of tumor development and metastasis. When
testing the abilities of 5-8F cells to migrate/invade
through the 8-μm pores on the polycarbonate membrane
with or without pre-coated matrigel, we found that the
knock-down of endogenous EIF4G1 expression could sig-
nificantly reduce cell migration and invasion as compared
to the parental or shRNA-Ctrl cells (P < 0.05) (Figures 3B,
C).
Knock-down of EIF4G1 Inhibited in vivo Xenograft Tumor 
Growth
In addition to examining the biological functions of
EIF4G1 in vitro, we also assessed the in vivo function of
EIF4G1  in a xenograft tumor transplantation model.
After subcutaneously transplanting the cells containing
shRNA-Ctrl or shRNA-EIF4G1  lentiviral vectors into
nude mice, we monitored the tumor growth over a 25-day
period. As shown in Figure 4A, by measuring the tumor
weights, we found that shRNA-EIF4G1 cells gave rise to
significantly smaller tumors than shRNA-Ctrl cells did (P
< 0.05). Immunohistochemistry assay revealed that pro-
tein expression of EIF4G1 was significantly decreased in
the tumors induced by shRNA-EIF4G1 cells compared to
those induced by shRNA-Ctrl cells (Figure 4B), which was
in consistent with the in vitro results in cells transfected
with shRNA-EIF4G1 or the control vectors (Figure 2A).
EIF4G1 Inhibited the Expression of PDCD4 in NPC cells
The above results indicated that over-expression EIF4G1
may play an important role in promoting the develop-
Table 1: Protein expression of EIF4G1 in NPC and NP and Correlation of clinicopathological features of the patients with 
NPC and expression of EIF4G1 protein
EIF4G1 protein expression
Characteristics N Negative(n) Low(n) Medium(n) High(n) P value
Group
NPC 132 2 27 41 62
NP 53 4 26 19 4 p = 0.000
Sex
Male 94 2 19 31 42
Female 38 0 8 10 20 p = 0.477
Age
≥45 years 81 2 15 24 40
< 45 years 51 0 12 17 22 p = 0.557
Smoking
No 100 0 21 29 50
Yes 32 2 6 12 12 p = 0.226
T classfication
T1+T2 91 2 22 29 38
T3+T4 41 0 5 12 24 p = 0.039*
N classfication
N0+N1 57 2 14 22 19
N2+N3 75 0 13 19 43 p = 0.008*
M classfication
M0 127 2 26 40 59
M 1 50113p = 0.625
Clinical stage
I+II 2 11 16 11
III+IV 41 0 16 25 51 p = 0.003*
* p < 0.05Tu et al. Molecular Cancer 2010, 9:78
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ment of NPC. We further examined the effect of EIF4G1
on the expression of PDCD4, a key tumor suppressor pro-
tein interacting with EIF4G1  and controlling tumor
growth and invasion [19]. We speculated that reducing
the levels of EIF4G1 activates the effects of PDCD4. To
test this hypothesis, we measured the protein levels of
PDCD4 in cells deficient of EIF4G1. Comparing to the
parental 5-8F cells and cells containing the control vector,
EIF4G1-deficient cells had increased levels of PDCD4
protein (Figure 5A). Our results suggest that EIF4G1 may
be involved in the development of NPC by antagonizing
the effect of PDCD4.
Discussion
It is well known that the majority of NPC deaths result
from tumor metastases rather than from primary tumors.
However, the molecular mechanisms underlying the reg-
ulation of tumor cell invasion and metastasis of NPC
remain incompletely understood. EIF4G1, a member of
the translational initiation factor family, is recognized as
the central organizing protein in the recruitment of
mRNA during translational initiation. Gradually accumu-
lated evidences indicate that increased EIF4G1 expres-
sion may play an oncogenic role and promote the process
of tumorigenesis. For instance, over-expression of
EIF4G1 has been found in inflammatory breast cancer
(IBC) and promotes the formation of IBC tumor emboli
by enhancing translation of IRES-containing p120
mRNA, which facilitated tumor cell survival [15]. In addi-
tion, frequent amplification of EIF4G1 on chromosome
3q27.1 and over-expression of EI4G1 mRNA was also dis-
played in lung cancer and hypopharyngeal cancer [13,14],
which suggest the involvement of EIF4G1 in tumorigene-
sis [11,20]. Yet, it remains largely unknown about the role
of EIF4G1 in the pathogenesis of NPC.
In the previous microarray study, we found that the lev-
els of EIF4G1 mRNA in NPC were increased compared to
noncancerous nasopharyngeal tissues [7]. In this report,
we further presented the proof that EIF4G1 was over-
expressed at both mRNA and protein levels in NPC tis-
sues and cell lines. Furthermore, we found that EIF4G1
over-expression was significantly associated with T clas-
sification, lymph node involvement, and clinical stages of
NPC patients. Our results also indicated that EIF4G1
protein expression was inversely correlated with patients'
overall survival time. NPC patients with higher expres-
sion levels of EIF4G1 protein had shorter survival time,
and the protein levels of EIF4G1 were an independent
prognostic factor. These results suggested the clinical sig-
nificance of EIF4G1 as a biomarker for NPC prognosis.
Table 2: Summary of univariate and multivariate Cox regression analysis of overall survival duration
Univariate analysis Multivariate analysis
Parameter P HR 95%CI P HR 95%CI
Age
> 45 vs. ≤ 45 years 0.497 1.252 0.655-2.391
Gender
Male vs. female 0.966 1.015 0.516-1.997
Smoking
No vs. Yes 0.239 0.628 0.290-1.362
T classification
T1-T2 vs. T3-T4 0.122 1.631 0.877-3.031
N classification
N0-N1 vs. N2--N3 0.032 2.034 1.062-3.898 0.455 1.393 0.584-3.323
M classification
M0 vs. M1 0.492 1.662 0.390-7.073
Clinical stage
I-II vs. III-IV 0.023 2.465 1.132-5.368 0.360 1.629 0.572-4.638
EIF4G1 expression
High expression vs. Low 
expression*
0.014 3.678 1.308-10.344 0.027 3.251 1.147-9.214
*High expression: medium and high expression; Low expression: negative and low expression;Tu et al. Molecular Cancer 2010, 9:78
http://www.molecular-cancer.com/content/9/1/78
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To understand the biological functions of EIF4G1, we
employed the loss-of-function approach, that is, by
knocking down the expression level of endogenous
EIF4G1. To achieve this purpose, we chose to use NPC 5-
8F cells, a cell line with high tumorigenic and metastatic
ability. The 5-8F cells exhibit the highest expression levels
of endogenous EIF4G1 in all the six NPC cell lines exam-
ined, and thus represent an ideal model for our study.
Using this system, we identified the roles of EIF4G1 in
promoting cell proliferation, cell cycle, migration, and
invasion; we further found that EIF4G1 could enhance
tumorigenesis in vivo. These results strongly suggest an
oncogenic role of EIF4G1 in NPC development.
EIF4G1 may be used as a useful molecular marker for
NPC and an indicator for tumor progression and progno-
sis. In combination with other biomarkers of NPC,
EIF4G1 would be useful for novel therapeutic strategies.
Assembly of the EIF4E/EIF4G complex plays a central
role in the regulation of gene expression at the level of
translation initiation. This complex is regulated by the
4EBP1, a translational repressor that inhibits the function
of eukaryotic translation initiation factor 4E (EIF4E),
which compete with EIF4G1 for binding to eIF4E  and
have tumor-suppressor activity[21]. To pharmacologi-
cally mimic 4E-BP function Moerke et al developed the
most potent small-molecule compound 4EGI-1 for dis-
rupting  EIF4E/EIF4G association, which inhibited cap-
Figure 2 Reduced expression of EIF4G1 inhibited cell proliferation. A. Western blotting assay shows significantly decreased protein expression 
of EIF4G1 in shRNA-EIF4G1 cells comparing to shRNA-Ctr and the parental 5-8F cells. β-actin was used as the internal control. B. The cell growth of 
parental 5-8F cells and their stable derivatives, shRNA-Ctrl and shRNA-EIF4G1, were examined by MTT assay over a seven-day period. *P < 0.05, as com-
pared to 5-8F and shRNA-Ctrl cells.Tu et al. Molecular Cancer 2010, 9:78
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dependent translation but not initiation factor indepen-
dent translation. While 4EGI-1 displaces EIF4G  from
EIF4E, it effectively enhances 4EBP1, a translational
repressor that inhibits the function of eukaryotic transla-
tion initiation factor 4E (EIF-4E), association with EIF4E
both in vitro and in cells, and suppressed cell prolifera-
tion [22,23]. Additionally, EIF4G1 has been reported to
implicate in another signal pathway. For example, EIF4A/
EIF4G complex has been shown to be involved in the key
regulation of translation initiation. Tumor suppressor
PDCD4 [24,25] could compete with EIF4A for binding to
EIF4G1 and thus inhibit the initialization of translation
[26]. Although PDCD4 is known to be a key regulator
that controls tumor growth and invasion [27], the role of
PDCD4 in NPC progression remains unclear. Recently, in
a microarray study, we observed a significant down-
expression of PDCD4 in NPC samples [7]. We therefore
speculated that EIF4G1 may play a role in NPC by inhib-
iting the functions of PDCD4. In the present study, we
found that the reduction of endogenous EIF4G1 protein
expression increased the expression levels of PDCD4.
This result supports the potential involvement of EIF4G1
in regulating PDCD4 expression.
In summary, our results provided the first evidence that
EIF4G1 may be involved in the development of NPC. In
addition, we also demonstrated that EIF4G1 could serve
as a biomarker for the prognosis of NPC. Further works
are needed to investigate the mechanisms and pathways
of NPC pathogenesis mediated by EIF4G1.
Materials and methods
Cell Culture and Sample Collection
NPC cell lines 5-8F, 6-10B, CNE2, HONE1, HNE1, and
SUNE1 were maintained in RPMI 1640 culture medium
Figure 3 Reduced EIF4G1 expression inhibited cell migration, invasion and cell cycle progression. A. Cell cycle was determined by FACS Caliber 
Cytometry. Cell migration (B) and invasion (C) capabilities of parental 5-8F cells and their stable derivatives, shRNA-Ctrl and shRNA-EIF4G1, were exam-
ined using transwell assay. Data were presented as mean ± SD for three independent experiments. *P < 0.05, as compared to shRNA-Ctrl and 5-8F cells.Tu et al. Molecular Cancer 2010, 9:78
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supplemented with 10% newborn calf serum (NBCS)
(PAA Laboratories, Austria). NP69, an immortalized
human nasopharyngeal epithelial cell line, was grown in
defined-KSFM medium supplemented with EGF (Invitro-
gen, Carlsbad, CA). All of the cell lines were incubated in
a humidified chamber with 5% CO2 at 37°C. Seven pri-
mary NPC tissues, 5 noncancerous nasopharyngeal tis-
sues, 132 paraffin-embedded NPC specimens (107 cases
with prognosis information), and 53 noncancerous paraf-
fin-embedded nasopharyngeal specimens were obtained
from People's Hospital of Zhongshan City, China, at the
time of diagnosis before any therapy. An informed con-
sent was obtained from each patient. All freshly collected
samples were immediately stored in liquid nitrogen.
Real-time PCR
Real-time PCR was performed to measure the expression
of  EIF4G1 mRNA in NPC cell lines, tumor tissues, or
normal nasopharyngeal tissues using SYBR Premix Ex
Taq (Takara, Japan) as described previously [28]. The
primers used were: forward 5'-TTGTGGATGATGGTG-
GCT-3' and reverse 5'-TTATCTGTGCTTTCTGTG-
GGT-3'. GAPDH was used as an internal control and the
primers were: forward 5'-GCACCGTCAAGGCT-
GAGAAC-3' and reverse 5'-TGGTGAAGACGCCAGT-
GGA-3'. Each measurement was repeated three times.
Immunohistochemistry
Paraffin sections (3 μm) from 132 NPC and 53 nasopha-
ryngeal samples were deparaffinized in 100% xylene and
re-hydrated in descending ethanol series according to
standard protocols [7]. Heat-induced antigen retrieval
was performed in 10 mM citrate buffer for 2 min at
100°C. The endogenous peroxidase activity and non-spe-
cific antigens were blocked with peroxidase blocking
reagent containing 3% hydrogen peroxide and serum. The
slides were incubated with rabbit anti-human EIF4G1
antibody (1:50) (Cell Signaling Technology, CA, USA) for
1 h at 37°C. After washing, the sections were incubated
with biotin-labeled goat anti-rabbit IgG antibody for 10
Figure 4 Reduced EIF4G1 expression inhibited cell colony formation and xenograft tumor growth in vivo. A. The cell clone ability of parental 
5-8F cells and their stable derivatives, shRNA-Ctrl and shRNA-EIF4G1, were examined by plate colony formation assay. *P < 0.05, as compared to 5-8F 
and shRNA-Ctrl cells. B. 5-8F cells containing shRNA-Ctrl or shRNA-EIF4G1 lentiviral vectors were injected into nude mice (n = 6 for each group). After 
25 d, tumors were harvested and weighted. Data are presented as mean ± SD. *P < 0.05 as compared to shRNA-EIF4G1 cells. C. EIF4G1 protein expres-
sion was markedly decreased in xenograft tumors induced by shRNA-EIF4G1 cells comparing to that induced by shRNA-Ctrl cells.Tu et al. Molecular Cancer 2010, 9:78
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m i n  a t  r oo m  t e m pe r a t u r e  f o l l o w ed  b y  i n cu ba t i o n  wi t h
streptavidin-conjugated horseradish peroxidase (HRP)
(Maixin Inc, China). The peroxidase reaction was devel-
oped with 3,3-diaminobenzidine chromogen solution in
DAB buffer substrate. The slides were reviewed and
scored independently by two pathologists blinded to the
clinical parameters. The staining intensity was scored as
described [29,30]. The extent of the staining, defined as
the percentage of positive staining cells in relation to the
whole field, was scored on a scale of 0 to 3 as 0: < 10%; 1:
10-25%; 2: 26-75%; and 3: ≥ 76%. The sum of the staining-
intensity and staining-extent scores (0-6) was used as the
final staining score for EIF4G1. For statistical analysis, a
final staining score of 0, 1~2, 3~4, and 5~6 were respec-
tively considered to be negative, low, medium, and high
expression levels.
Establishment of NPC 5-8F cell line with stably expressing 
shRNA-EIF4G1
The construction of lentiviral vector of shRNA targeting
EIF4G1 and establishment of NPC 5-8F cell line stably
expressing shRNA had been described previously
[17,18,31]. In brief, we selected one sequence for target-
ing the EIF4G1 gene using the BLOCK-It RNAi Designer
(Invitrogen, Carlsbad, CA). The preparation of lentiviral
vectors expressing human EIF4G1  short hairpin RNA
(shRNA) was performed using the BLOCK-It Lentiviral
RNAi Expression System (Invitrogen, Carlsbad, CA), fol-
lowing the manufacturer's instruction and replication-
incompetent lentivirus was produced by cotransfection of
the pLenti6/EIF4G1  expression vector and ViraPower
packaging mix (Invitrogen) containing an optimized mix-
ture of three packaging plasmids: pLP1, pLP2, and pLP/
VSVG into 293FT cells. NPC 5-8F cells were infected
with lentiviral particles containing specific or negative
control vectors and selected for stable integrants by cul-
turing a complete medium containing blasticidin. After
15 days of selection, there were no viable cells in mock
wells and discrete blasticidin resistance colonies. The
total RNA of these cell clones was isolated, and the levels
of EIF4G1 mRNA were measured using real-time PCR as
described above.
Western blot Analysis
Cells were lysed in RIPA Buffer (50 mM Tris-HCl pH 8.0,
1 mM EDTA pH 8.0, 5 mM DTT, 2% SDS), and protein
concentration was determined using BCA assay (Beyo-
time Inc, China). Total protein (30 μg) was resolved using
a 10% SDS-PAGE gel and transferred onto a polyvi-
nylidene fluoride (PVDF) membrane. The primary anti-
bodies used were rabbit polyclonal anti-EIF4G1
antibody(1:500), anti-ACTB  antibody(1:400) (both from
Santa Cruz Biotechnology, CA, USA) and PDCD4(1:500,
Abcam Inc., Cambridge, MA). An HRP-conjugated anti-
rabbit IgG antibody was used as the secondary antibody
(Zhongshan Inc, China).
Cell Proliferation and Cell Cycle Analyses
Cell proliferation was analyzed using MTT assay (Sigma,
St. Louis, USA). Briefly, 1 × 103 cells were seeded into a
96-well plate with quadruplicate repeat for each condi-
tion. After 72 h of incubation, MTT reagent was added to
each well and incubated for 4 h. The formazan crystals
formed by viable cells were then solubilized in DMSO
and measured at 490 nm for the absorbance (A) values.
Each experiment was performed in triplicates.
To evaluate cell cycle distribution, cells were seeded on
10 cm-diameter plates in RPMI 1640 culture medium
containing 10% NBCS. After 48 h of incubation, a total of
1 × 106 cells were harvested, rinsed with cold PBS, and
fixed with 70% ice-cold ethanol for 48 h at 4°C. Fixed cells
were rinsed with cold PBS followed by incubation with
Figure 5 Reduced EIF4G1 expression activated the expression of PDCD4 protein. A. Protein expression of PDCD4 was increased in shRNA-EIF4G1 
cells compared to shRNA-Ctrl cells and the parental 5-8F cells. Data were presented as mean ± SD. *P < 0.05.Tu et al. Molecular Cancer 2010, 9:78
http://www.molecular-cancer.com/content/9/1/78
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PBS containing 10 μg/mL propidium iodide and 0.5 mg/
mL RNase A for 15 min at 37°C. The DNA content of
labeled cells was acquired using FACS Caliber cytometry
(BD Biosciences). Each experiment was performed in
triplicates.
In vitro Cell Migration and Invasion Assays
Cells growing in the log phase were treated with trypsin
and re-suspended as single-cell solution. A total of 1 ×
105 cells were seeded on a fibronectin-coated polycarbon-
ate membrane insert in a transwell apparatus (Corning
Inc., Corning, NY). In the lower chamber, 600 μl of RPMI
1640 with 10% NBCS was added as chemoattractant.
After the cells were incubated for 12 h, the insert was
washed with PBS, and cells on the top surface of the
insert were removed by a cotton swab. Cells adhering to
the lower surface were fixed with methanol, stained with
Giemsa, and counted under a microscope in five prede-
termined fields (×200). For the Matrigel invasion assay,
the procedure was similar with the cell migration assay,
except that the transwell membrane was precoated with
ECMatrix™ and the cells were incubated for 14 h. All
assays were independently repeated at least three times.
Colony Formation Assay
About 100 cells were added to each well of a 6-well cul-
ture plate, and each cell group contained 2 wells. After 2
weeks of incubation, cells were washed twice with PBS
and stained with Giemsa solution. The number of colo-
nies containing ≥ 50 cells was counted under a micro-
scope. The colony formation efficiency was calculated as:
efficiency = (number of colonies/number of cells inocu-
lated) × 100%. Each experiment was performed in tripli-
cates.
Growth of Tumor Xenografts in Nude Mice
All animal studies were conducted in accordance with the
principles and procedures outlined in the National Insti-
tutes of Health (NIH) Guide for the Care and Use of Ani-
mals under assurance number A3873-1. Nude mice of 4
to 6 weeks old (n = 6) were purchased from the Animal
Center, Southern Medical University. A total of 1 × 106
cells growing in log phase were re-suspended in serum-
free RPMI 1640 medium and injected subcutaneously
into the nude mice. To minimize inter-individual varia-
tion, cells containing control vector and cells containing
shRNA-EIF4G1  vector were injected symmetrically to
the either flank of the same mice. After 25 d, mice were
sacrificed and tumors isolated and weighted. EIF4G1 pro-
tein levels in the xenograft tumors were examined using
immunohistochemistry assay.
Statistical analysis
All data were analyzed for statistical significance using
SPSS 13.0 software. The Mann-Whitney U test was
applied to the analysis of relationship between EIF4G1
expression levels and clinicopathologic characteristics.
Survival analysis was performed using Kaplan-Meier
method (the log-rank test). Multivariate Cox propor-
tional hazards method was used for analyzing the rela-
tionship between the variables and patient's survival
time. One-way ANOVA was used to determine the differ-
ences between groups for all in vitro and in vivo analyses.
A P value of less than 0.05 was considered statistically sig-
nificant.
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